Research programme: rheumatoid arthritis therapy - Oxford GlycoSciences
Latest Information Update: 19 Jun 2007
At a glance
- Originator UCB; University of Oxford
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 19 Jun 2007 Discontinued - Preclinical for Rheumatoid arthritis in United Kingdom (unspecified route)
- 13 Jan 2003 No development reported - Preclinical for Rheumatoid arthritis in United Kingdom (unspecified route)
- 06 Apr 2000 Preclinical development for Rheumatoid arthritis in United Kingdom (Unknown route)